Assessment of time-dependent structural alteration of rituximab in patients
Not Applicable
- Conditions
- follicular lymphoma or diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000016713
- Lead Sponsor
- Department of Clinical Pharmacology & Therapeutics, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who could not be took blood sampling at designated time points Patients who need legal representative
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of rituximab and the structural alteration of its carbohydrate chains or other flagments
- Secondary Outcome Measures
Name Time Method In vitro assessment of pharmacological effect of isolated rituximab from patients Clinical effects (response rate, blood test values, bone marrow infiltration) Adverse events (clinical test values, presence or absence of infusion reaction)